Inmarsat Takes Another Leap Forward With ELERA, The Global Network for IoT, Safety and Mission Critical Connectivity
12.8.2021 13:12:00 EEST | Business Wire | Press release
In its second major announcement in two weeks, Inmarsat is today unveiling Inmarsat ELERA; a global narrowband network that is ideally suited to the rapidly evolving world of the Internet of Things (IoT) and for global mobility customers, including aviation, maritime, governments and select enterprises.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210812005417/en/
Inmarsat Takes Another Leap Forward With ELERA, The Global Network for IoT, Safety and Mission Critical Connectivity (Photo: Business Wire)
“ELERA is perfectly suited to the needs of the connected IoT world,” said Rajeev Suri, CEO, Inmarsat. “Global reach, extraordinary resilience, faster speeds, smaller and lower cost terminals are all part of ensuring that we remain ahead of others in meeting the needs of our customers.”
“ELERA is a further sign of a company with true momentum and one that is delivering new innovations and strong performance,” continued Suri. “I expect that Inmarsat will grow strongly in 2021 compared to the previous year, and that growth will span most of our business units. Our progress was evident in the first half, where we saw strong growth in revenue and EBITDA and robust cash flow. We have sharpened our strategy to focus on driving growth, accelerate decision making, launch new innovations, and are creating a more commercially focused, customer-centric culture.”
ELERA builds on Inmarsat’s #1 position in Mobile Satellite Services (MSS) and will be a springboard for innovation, unlocking, accelerating and scaling pioneering use cases on land, at sea and in the air. Its foundation is Inmarsat’s world class L-band network and incorporates new innovations ranging from higher speeds to smaller, low cost terminals and [the previously announced] Inmarsat-6 satellites, the first of which (I-6 F1) is scheduled to launch before the end of the year.
Coming just 14 days after Inmarsat announced ORCHESTRA, the world’s first network to combine GEO, LEO and 5G into one harmonious global communications solution, ELERA underlines Inmarsat’s strategic focus on the global mobility segment of satellite communications. It is also a signal of a company with momentum, delivering major technological innovations and growth.
The unique capabilities of ELERA, combined with Inmarsat’s superior spectrum and the ideally suited orbital position of its satellite networks, will make it the essential catalyst for new IoT use cases, across everything from autonomous transport and unmanned aerial vehicles (UAV) to industrial and agricultural IoT applications.
ELERA Innovation
ELERA is built on Inmarsat’s market leading L-band network, which already delivers the world’s most reliable and flexible global connectivity service with unique resilience in all conditions and full global redundancy. It supports everything from worldwide maritime and aviation safety services and humanitarian missions to IoT applications across agritech, transportation and utilities, among many others.
The new innovations that the company is investing in to bring to market in the near future include spectrum management technology to deliver L-band speeds up to 1.7Mbps, the smallest footprint, low cost L-band terminal and two new L-band satellites, which are the largest and most sophisticated commercial communication satellites ever created.
The new spectrum management capabilities (known as Carrier Aggregation) being incorporated into the ELERA network will deliver the fastest speeds globally available to L-band customers, far outstripping the capabilities of any other worldwide L-band network.
Live customer trials in commercial aviation are scheduled to start during the course of 2022 and this technology will be rolled out across a range of sector specific applications for Inmarsat’s mobility, government and IoT customers over the coming few years.
ELERA will also see the creation of the smallest footprint, low cost terminal for L-band users, delivering the ideal framework for satcom IoT at scale, with supporting cloud-based management, for vertical sectors such as infrastructure, rail, logistics, mining, agriculture, government, maritime and aviation.
Inmarsat is launching two new satellites to enhance the ELERA network. The I-6 satellites, the first of which is scheduled to launch at the end of 2021, are the largest and most sophisticated commercial communications satellites ever built.
The L-band capacity on each I-6 satellite will be substantially greater than Inmarsat’s 4th generation spacecraft and, among other enhancements, they will deliver 50% more capacity per beam; meaning that much more data can be carried over the same geographical area, in addition to unlimited beam routing flexibility.
ELERA will also deliver a major extension to Inmarsat’s portfolio of voice-enabled devices, bringing new capabilities and innovations to hundreds of thousands of customers. This initiative represents our commitment to voice service innovation and underlines the company’s long-term commitment to the handheld voice services over satellite market.
“ELERA is the exciting vision of how Inmarsat is planning to transform the capabilities offered to IoT and mobility customers for years to come and confirms our long-term commitment to L-band services. We will be sharing further detail on these innovations with our partner community in the coming months and continue our programme of announcements as we achieve major milestones.” said Rajeev Suri, CEO, Inmarsat.
The investments in ELERA are already included in Inmarsat’s current CAPEX plans and guidance.
ENDS
Notes to Editors
ABOUT INMARSAT
Inmarsat is the world leader in global, mobile satellite communications. It owns and operates the world’s most diverse global portfolio of mobile telecommunications satellite networks, and holds a multi-layered, global spectrum portfolio, covering L-band, Ka-band and S-band, enabling unparalleled breadth and diversity in the solutions it provides. Inmarsat’s long-established global distribution network includes not only the world’s leading channel partners but also its own strong direct retail capabilities, enabling end to end customer service assurance.
The company has an unrivalled track record of operating the world’s most reliable global mobile satellite telecommunications networks, sustaining business and mission critical safety and operational applications for more than 40 years. It is also a major driving force behind technological innovation in mobile satellite communications, sustaining its leadership through a substantial investment and a powerful network of technology and manufacturing partners.
Inmarsat operates across a diversified portfolio of sectors with the financial resources to fund its business strategy and holds leading positions in the Maritime, Government, Aviation and Enterprise satcoms markets, operating consistently as a trusted, responsive and high-quality partner to its customers across the globe.
For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005417/en/
Contact information
Media enquiries:
Jonathan Sinnatt / Matthew Knowles
Corporate Communications
Tel: +44 (0)788 960 5272 / +44 (0) 7725 476 507
press@inmarsat.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
